<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580124</url>
  </required_header>
  <id_info>
    <org_study_id>PV3572</org_study_id>
    <nct_id>NCT01580124</nct_id>
  </id_info>
  <brief_title>CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study</brief_title>
  <acronym>CHASE-AF</acronym>
  <official_title>CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design:&#xD;
&#xD;
      Randomized prospective comparison of pulmonary vein isolation alone versus a strategy aiming&#xD;
      for atrial fibrillation termination by using a stepwise approach consisting of pulmonary vein&#xD;
      isolation, biatrial defragmentation aiming for fractionated electrograms and linear ablation&#xD;
      if required.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study protocol:&#xD;
&#xD;
      In patients randomized to PVI alone, the index procedure consists of wide circumferential&#xD;
      pulmonary vein isolation (1 cm distal of the PV ostium) including optional right atrial&#xD;
      isthmus ablation. Endpoint for PVI is entrance block as evaluated by a circumferential&#xD;
      mapping catheter during sinus rhythm at the end of the procedure. In all patients the NavX®&#xD;
      three-dimensional mapping system should be used. The St. Jude Medical Coolflex® or Coolpath®&#xD;
      catheters may be used at the operator's discretion.&#xD;
&#xD;
      In patients randomized to the strategy aiming for atrial fibrillation termination PVI is also&#xD;
      the initial step of the procedure followed by atrial defragmentation and eventual linear&#xD;
      ablation in case of atrial tachycardia aiming for acute restoration of sinus rhythm. The&#xD;
      procedural steps with regard to mapping and ablation of atrial fibrillation and consecutive&#xD;
      atrial tachycardia follow the previously described methods (8,9). After initial ablation the&#xD;
      previous antiarrhythmic drug treatment can be continued but no de novo antiarrhythmic drug&#xD;
      regiment should be applied. The primary endpoint of this study is recurrence of atrial&#xD;
      arrhythmias between 6 and 12 months after the initial ablation procedure.&#xD;
&#xD;
      In both study arms, the same CE certified catheters will be used. Usually, the setting&#xD;
      consists of on decapolar catheter positioned in the coronary sinus, one circumferential&#xD;
      mapping catheters for mapping of the pulmonary veins, one quadripolar catheter for mapping&#xD;
      the right atrium. In both study groups a externally irrigated catheter for mapping and&#xD;
      ablation will be used (CoolFlex/ Coolpath as mentioned above).&#xD;
&#xD;
      Sample size calculation:&#xD;
&#xD;
      According to the assumption of a difference of 30 % regarding the primary endpoint (power 80,&#xD;
      alpha=0.05) 70 patients have to be included. Considering a potential drop out of 10 % 160&#xD;
      patients should be included. However, an adaptive statistical plan is applied (Prof.&#xD;
      Wegscheider, University Hospital Hamburg).&#xD;
&#xD;
      Follow up and repeat procedures:&#xD;
&#xD;
      Crossover between the two treatment options should be avoided. Previous antiarrhythmic drug&#xD;
      treatment can be continued until month 6 after the index procedure is completed. Repeat&#xD;
      procedures between month 0 and 3 should be avoided. Repeat procedures should be planned&#xD;
      between month 3 and 6 after the index procedure. The initial approach of the repeat procedure&#xD;
      is the same as during the index procedure (Figure 1). Thus, in patients randomized for PVI&#xD;
      alone, PVI will be repeated in case of reconnection of the veins. In the setting of complete&#xD;
      block of all pulmonary veins also patients randomized to PVI alone will receive a substrate&#xD;
      modification as in the other group. Patients randomized to the ablation procedure aiming for&#xD;
      AF termination will again receive a 'complete' procedure including assessment of PVI and&#xD;
      ablation of atrial tachycardias and atrial fibrillation.&#xD;
&#xD;
      Follow-up:&#xD;
&#xD;
      All patients will be seen in the outpatient clinic every 3 month during the 12 month study&#xD;
      period. The visit will include ECG and Holter ECG recordings. Additionally, echocardiography&#xD;
      and interrogation of pacemaker will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of atrial arrhythmia during 12 months follow up</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of periprocedural complications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PVI alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation alone in persistent atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVI + Defragmentation + linear lesions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AF ablation continuation aiming for AF termination</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI alone</intervention_name>
    <description>PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation</description>
    <arm_group_label>PVI alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI + Defragmentation + linear lesions</intervention_name>
    <description>PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination</description>
    <arm_group_label>PVI + Defragmentation + linear lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Persistent atrial fibrillation &gt; 7 days or previous cardioversion&#xD;
&#xD;
          -  Obtained written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Previous operative or interventional treatment of atrial fibrillation&#xD;
&#xD;
          -  Paroxysmal atrial fibrillation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Contraindication for oral anticoagulation&#xD;
&#xD;
          -  Contraindication for heparin administration&#xD;
&#xD;
          -  Transient factors causing atrial fibrillation (e.g. Hyperthyroidism)&#xD;
&#xD;
          -  Drug and alcohol abuse&#xD;
&#xD;
          -  Severe underlying heart disease with left atrial enlargement &gt; 60 mm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Willems, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Steven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/26700836</url>
    <description>PubMed</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>April 28, 2019</last_update_submitted>
  <last_update_submitted_qc>April 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

